Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Retrospective study of Isa-pom-dex in relapsed/refractory AL amyloidosis finds overall heme response at 3, 6, and 12 months was 91.7%, 92%, and 87.5%; median OS and EFS were 53 and 41 mos; 66% of pts achieved best response in 3 mos.”
Title: A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosis
Authors: Sargam Rachit Vohra, Sriram Ravichandran, Darren Foard, Ana Martinez-Naharro, Lucia Venneri, Marianna Fontana, Carol J. Whelan, Philip N. Hawkins, Julian Gillmore, Helen J. Lachmann, Shameem Mahmood, Ashutosh D. Wechalekar
You can read the Full Article in Haematologica.
More posts featuring Robert Orlowski.
